Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

752.02 -25.23 (-3.25%)
Streaming Delayed Price Updated: 11:21 AM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals ↗
Regeneron Pharmaceuticals (REGN) is a top value stock with a low P/E ratio, strong profitability, and excellent financial health, offering a potential margin of safety for investors. 
Via Chartmill
News headline image
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J? ↗
The company is looking to take on Johnson & Johnson in treating patients with a precursor to multiple myeloma. 
Via Investor's Business Daily
News headline image
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials ↗
Via Stocktwits
Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon ↗
Via Stocktwits
News headline image
Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder ↗
Regeneron's Phase 3 trial of garetosmab showed a 90%+ reduction in new bone lesions for FOP, with no deaths and good safety over 56 weeks. 
Via Benzinga
Topics Death
News headline image
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products,... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy ↗
Libtayo plus chemotherapy showed superior survival and response rates over five years in advanced NSCLC patients without EGFR, ALK, or ROS1 mutations. 
Via Benzinga
News headline image
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Cash-Producing Stocks That Concern Us
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth
The global economy is currently grappling with a projected deceleration in GDP growth, a situation severely exacerbated by an unprecedented escalation of U.S. tariffs. These twin forces are creating a... 
Via MarketMinute
Topics Economy Supply Chain World Trade
News headline image
What's Happening With Regeneron Pharmaceuticals Stock On Monday? ↗
Regeneron's Phase 3 trials for cat and birch allergies show significant symptom relief and strong safety results, paving the way for future development. 
Via Benzinga
News headline image
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks to Buy on the Dip ↗
The market may be overlooking these companies' long-term potential. 
Via The Motley Fool
Topics Government World Trade
News headline image
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors ↗
Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise. 
Via Benzinga
News headline image
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' ↗
Can anything beat out Dupixent's "compelling bar" for effectiveness? 
Via Investor's Business Daily
News headline image
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades' ↗
Cisco reported fourth-quarter revenue of $14.67 billion, and there was a bout of profit taking, Cerity Partners' Jim Lebenthal says. 
Via Benzinga
News headline image
REGENERON PHARMACEUTICALS (NASDAQ:REGN): A Prime Value Investing Candidate with Strong Fundamentals ↗
Discover REGN, a top value investing stock. It boasts strong fundamentals, low P/E ratios, high profitability, and solid financial health, trading below its intrinsic worth. 
Via Chartmill
News headline image
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Where Regeneron Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data ↗
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
News headline image
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top S&P500 movers in Monday's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.